Mankowski Michal A, Bae Sunjae, Strauss Alexandra T, Lonze Bonnie E, Orandi Babak J, Stewart Darren, Massie Allan B, McAdams-DeMarco Mara A, Oermann Eric K, Habal Marlena, Iturrate Eduardo, Gentry Sommer E, Segev Dorry L, Axelrod David
Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA; Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
Am J Transplant. 2025 Apr;25(4):744-755. doi: 10.1016/j.ajt.2024.11.008. Epub 2024 Nov 15.
Developing real-world evidence from electronic health records (EHR) is vital to advancing kidney transplantation (KT). We assessed the feasibility of studying KT using the Epic Cosmos aggregated EHR data set, which includes 274 million unique individuals cared for in 238 US health systems, by comparing it with the Scientific Registry of Transplant Recipients (SRTR). We identified 69 418 KT recipients who underwent transplants between January 2014 and December 2022 in Cosmos (39.4% of all US KT transplants during this period). The demographics and clinical characteristics of recipients captured in Cosmos were consistent with the overall SRTR cohort. Survival estimates were generally comparable, although there were some differences in long-term survival. At 7 years posttransplant, patient survival was 80.4% in Cosmos and 77.8% in SRTR. Multivariable Cox regression showed consistent associations between clinical factors and mortality in both cohorts, with minor discrepancies in the associations between death and both age and race. In summary, Cosmos provides a reliable platform for KT research, allowing EHR-level clinical granularity not available with either the transplant registry or health care claims. Consequently, Cosmos will enable novel analyses to improve our understanding of KT management on a national scale.
从电子健康记录(EHR)中生成真实世界证据对于推进肾移植(KT)至关重要。我们通过将Epic Cosmos汇总的EHR数据集与移植受者科学注册系统(SRTR)进行比较,评估了使用该数据集研究KT的可行性。Epic Cosmos数据集包含在美国238个医疗系统中接受治疗的2.74亿独特个体。我们确定了2014年1月至2022年12月期间在Cosmos中接受移植的69418名KT受者(占该时期美国所有KT移植的39.4%)。Cosmos中记录的受者人口统计学和临床特征与整个SRTR队列一致。生存估计总体上具有可比性,尽管长期生存存在一些差异。移植后7年,Cosmos中的患者生存率为80.4%,SRTR中的为77.8%。多变量Cox回归显示,两个队列中临床因素与死亡率之间的关联一致,死亡与年龄和种族之间的关联存在细微差异。总之,Cosmos为KT研究提供了一个可靠的平台,允许进行移植登记或医疗保健索赔无法提供的EHR级临床粒度分析。因此,Cosmos将能够进行新颖的分析,以提高我们在全国范围内对KT管理的理解。